Category: St. Jude Medical
St. Jude kicks off the EnligHTN IV study, the 1st U.S. trial in a series evaluating the company's mult-electrode renal denervation system for patients with drug-resistant hypertension.
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
MassDevice.com looked at some of the most talked-about medical device companies, based on trends in Google searches for the last 30 days.
During the last month the medtech titans were flush with news from conferences, court rooms and Wall Street.
Dr. Richard Gilfillan, the 1st director of the Center for Medicare & Medicaid’s Innovation Center, is reportedly leaving by the end of this month to pursue “new opportunities.”
Dr. Richard Gilfillan, the 1st leader of the recently-created Center for Medicare & Medicaid Services Innovation Center, will hand over the reigns at the end of the month, and no replacement has yet been named.
St. Jude Medical's attempts to distance its next-generation Durata defibrillator leads from the high-profile Riata recall may be making inroads with investors, analysts and physicians.
Medical device maker St. Jude Medical (NYSE:STJ) is feeling pretty confident about public perception of its Durata defibrillator leads, which came under scrutiny amid a high-profile recall of its older Riata leads.
A federal judge shoots down Biosense Webster's bid to keep a trio of former sales reps from working for cardiac rhythm management rival St. Jude Medical.
Boston Scientific presents interim findings for the Vessix renal denervation system, touting positive 6-month results in the 1st series of patients from the REDUCE-HTN clinical trial.
Boston Scientific (NYSE:BSX) unveiled a snapshot of its REDUCE-HTN clinical trial at EuroPCR this month, with interim data from the initial 41 patients treated with the company's Vessix renal denervation system.
MassDevice.com columnist Stephen Simpson on St. Jude Medical's stock activity, as shares have hit the mid-$40s in recent weeks.
By Stephen Simpson